FILING BY "EXPRESS MAIL" UND NA 24615890US

20. 
Other items or information: Unexecuted Declaration and Power of Attorney

Express Mail Label Number

May 13, 7005
Date & Deposit

Form PTO-1390-MOD U. S. Department of Commerce Patent and Trademark Office ATTORNEY'S DOCKET NUMBER (REV 10-96) PD/4-32749A U.S. APPLICATION NO. (If known, see 37 CFR 1.5) TRANSMITTAL LETTER TO THE UNITED STATES **DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371** INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PCT/EP2003/012737 14 November 2003 (14.11.03) 15 November 2002 (15.11.02) TITLE OF INVENTION DRUG DELIVERY SYSTEM APPLICANT(S) FOR DO/EO/US MARGARET FORNEY PRESCOTT Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 1. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 2. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).  $\boxtimes$ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority 4. date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) 5.  $\boxtimes$ a. is transmitted herewith (required only if not transmitted by the International Bureau). b. Mas been transmitted by the International Bureau. (See Form PCT/IB/308) c. I is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)).

Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). <sub>4</sub>6. a. 

are transmitted herewith (required only if not transmitted by the International Bureau). have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. d. A have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included. 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. A change of power of attorney and/or address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).

## JC14 Rec'd PCT/PTO 13 MAY 2005

U.S. APPLICATION AD	10/534790 PCT/EP2003/012737 PD/4-327						19A			
The following fe								CAL	LCULATIO	NS PTO USE
								ONLI		
21. 🛭 Basi	c nationa	al fee 				• • • • •	\$300			
22. Examination Fee  If International preliminary examination report was prepared by USPTO										
and all claims satisfy provisions of PCT Article 33(1)-(4)										
⊠ All other situations										
·										
23. Search fee  If Search fee (37 CFR 1.445(a)(2)) has been paid on the international										
application to the USPTO as an International Searching Authority \$  ☑ If International Search Report was prepared and provided to the Office \$400										
All other situations										
TOTAL OF 21, 22 AND 23 =									900	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction										
thereof.	nied in ai	n electronic	meaium). In	e tee is \$250 for each a	addition	ai 50 sr	eets of paper o	r iraci	lion	
Total Sheets	Extra	sheets		ach additional 50 or fra id <b>up</b> to a whole numbe			RATE			
20 - 100 =		/50 =		0		X \$	250	\$		
Surcharge of \$130 for furnishing the oath of declaration later than   30										
months from the earliest claimed priority date (37 CFR 1.492(e)).  CLAIMS NUMBER FILED NUMBER EXTRA RATE										
Total claims		8	- 20 =	0	$\overline{}$	X \$	50	\$		
Independent cla		T CLAIM(S)	-3 =	) 0		× \$ + \$	200 360	\$		
TOTAL OF ABOVE CALCULATIONS =									900	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be								•		-
filed (Note 37 CFR 1.9, 1.27, 1.28).  SUBTOTAL =								\$	900	
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).										
TOTAL NATIONAL FEE =									900	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied										<del></del>
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +  TOTAL FEES ENCLOSED =								\$	900	
		<del></del>						/	Amount to	\$
								be:	refunded charged	\$
a.	k in the	amount of \$	· · ·	to cover the above	fees is	enclos	ed.		J. Laigua	7
b.   Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$900 to cover the above fees. A duplicate copy of this form is enclosed.										
c.   The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.										
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a)										
or (b)) must be filed and granted to restore the application to pending status.										
Send all correspondence to the address associated with Customer No. 001095, which is currently:										
Gregor C. Moughton										
Novartis Attorney for Applicant										
Corporate Intellectual Property Reg. No. 47,666 One Health Plaza, Building 104 (862) 778-2614										
East Hanover, NJ 07936-1080										